Allink Biotherapeutics Secures $42M Series A to Advance Oncology and Immunology Therapies

Beijing-based Allink Biotherapeutics, a clinical-stage biotechnology firm, has successfully raised $42 million in a Series A funding round. The round saw participation from Lanchi Ventures as the lead investor, followed by contributions from Legend Capital, Yuanbio Venture Capital, C&D Emerging Industry Equity Investment, and existing backers Med-Fine Capital and Gaorong Ventures.

The funds will accelerate the global development of Allink’s therapeutics, which target cancer and other serious diseases. The company is focused on next-gen treatments, leveraging its expertise in ADCs and bispecific antibody technology to address unmet medical needs.

Allink Biotherapeutics intends to use the funding to advance the global clinical trials of its leading drug candidates, ALK201 and ALK202, in Phase 1 studies across Australia, the United States, and China. These trials are pivotal for the company’s efforts to strengthen its international presence and progress its innovative treatments in oncology and immunology. Additionally, the investment will enable the development of new, highly competitive assets within these therapeutic areas, further expanding its portfolio.

In addition to clinical development, Allink will further enhance its proprietary bispecific antibody and ADC (antibody-drug conjugate) technology platform. This will allow the company to strengthen its approach to drug discovery, targeting some of the most pressing medical needs in cancer and immune-related diseases.

Founded in 2023, Allink Biotherapeutics develops novel, highly effective therapies, and the funding will accelerate the global expansion of its research and clinical activities.

CEO and founder Hui Feng expressed gratitude for the continued support of existing investors and the addition of new backers, emphasizing the importance of their belief in the company’s scientific capabilities. Feng noted that this funding will allow Allink to advance its diverse pipeline, including ADCs and bispecific antibodies, to address unmet needs in oncology and immunology.

Led by Dr. Hui Feng, founder and CEO, Allink Biotherapeutics is a clinical-stage biotechnology firm focused on leveraging its proprietary bispecific antibody and ADC platforms. The company is dedicated to developing a diverse pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics to transform treatment paradigms in oncology and immunology. Allink’s goal is to address unmet medical needs worldwide with drugs that can substantially impact patient care.

With fresh capital and strong R&D capabilities, the company plans for rapid growth across product development and corporate evolution. Lanchi Ventures, a lead investor, praised AllinkBio’s fast execution and Dr. Feng’s leadership, highlighting the company’s strong position in the competitive oncology space. Allink’s advanced ADC and bispecific antibody technologies are seen as promising solutions in targeted cancer therapeutics.